Where to Get Victoza: Access Routes, Costs, and the Facts

Victoza is one of the earlier GLP-1 medicines, and its history explains a lot about how it is prescribed today. This PlexusDx Education Hub guide covers what Victoza is, how it works, its approved uses, tolerability, and cost as of April 2026. Browse all Peptides & GLP-1 education

Victoza's place in GLP-1 history

Victoza is Novo Nordisk's brand of liraglutide — a once-daily GLP-1 receptor agonist first FDA-approved for type 2 diabetes in 2010, with a cardiovascular indication added in 2017. Liraglutide shares 97% sequence homology with native human GLP-1, which is part of why it became a reference point for the class that followed.

The receptor mechanism

Victoza engages the GLP-1 receptor across the pancreas, hypothalamus, and gastrointestinal tract — slowing gastric emptying, blunting post-meal glucose excursions, reducing appetite, and increasing satiety signaling. Its daily dosing schedule keeps the receptor engaged. Newer GIP/GLP-1 dual agonists such as tirzepatide add a second incretin receptor, but Victoza works through the GLP-1 pathway alone.

Approved uses and prescribing

Victoza is approved for specific indications per its label, and across the wider class approvals include type 2 diabetes (most compounds), chronic weight management (Wegovy, Saxenda, Zepbound), cardiovascular risk reduction in type 2 diabetes (several products), and obstructive sleep apnea in adults with obesity (Zepbound, 2024). The same liraglutide molecule under a different brand is not automatically interchangeable for coverage, so prescribing follows the brand's approved use.

Side effect profile

Gastrointestinal symptoms — nausea, vomiting, diarrhea, constipation — are the most commonly reported effects and are typically most pronounced during dose titration. Like every FDA-approved GLP-1 compound, Victoza carries the class boxed warning for thyroid C-cell tumor risk observed in rodent studies. Rare serious events include pancreatitis, gallbladder disease, and acute kidney injury in the context of dehydration.

Cost and legitimate access

Manufacturer list prices for FDA-approved branded products are typically $800–$1,600 per month at U.S. list as of April 2026. What you pay depends on insurance coverage, the FDA indication on the prescription, manufacturer savings-card eligibility, and whether a compounded alternative is available through a licensed 503A pharmacy pathway.

The genetics beneath any GLP-1 choice

PlexusDx does not sell, distribute, or prescribe Victoza or any therapeutic peptide outside its own Weight Management Protocols (which include semaglutide and tirzepatide). Whichever GLP-1 pathway compound you and your provider discuss, the underlying genetic architecture is the same. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including variants in FTO, GLP1R, and MC4R that shape your baseline GLP-1, appetite regulation, and energy-balance biology. Reading that profile before committing is the test before you invest approach.

Related reading on PlexusDx: Victoza vs Liraglutide, Victoza vs Tirzepatide, Where to Buy Victoza, Victoza Cost.

Disclaimer: This article is educational. PlexusDx does not sell, prescribe, or recommend dulaglutide, liraglutide, retatrutide, cagrilintide, or any other therapeutic peptide in this category beyond the semaglutide and tirzepatide products in its Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start upstream with the genetic context. Take the Precision Peptide Genetic Test to understand the pathway biology behind every GLP-1 decision.

Frequently Asked Questions

What is Victoza?

Victoza is Novo Nordisk's brand of liraglutide, a once-daily GLP-1 receptor agonist FDA-approved for type 2 diabetes since 2010 and for cardiovascular risk reduction in adults with type 2 diabetes since 2017. It works through the GLP-1 pathway to influence appetite, satiety, and glucose regulation.

How old is Victoza compared with newer GLP-1s?

Victoza was first approved in 2010, making it one of the earlier GLP-1 receptor agonists, with a cardiovascular indication added in 2017. Its liraglutide molecule shares 97% sequence homology with native human GLP-1 and is dosed daily rather than weekly, unlike several newer compounds.

Is Victoza the same as generic liraglutide?

Victoza is the brand name for liraglutide from Novo Nordisk. The molecule is liraglutide, but each brand of liraglutide is approved for its own indications and is not automatically interchangeable for coverage, so a prescriber matches the brand to the intended use.

Can the Precision Peptide Genetic Test predict my Victoza response?

No. It does not predict response to Victoza or any specific medication. It analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology — the upstream context that applies across every GLP-1 pathway compound.

Compare Victoza with related options in the PlexusDx Education Hub. Browse all Peptides & GLP-1 education